# DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

Source: https://onco.cc/trials/nct03714334/  
OnCo record `nct03714334` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2440 run by Clinica Universidad de Navarra, Universidad de Navarra, terminated.

## Summary

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma is a phase 1 interventional study registered as NCT03714334 by Clinica Universidad de Navarra, Universidad de Navarra, with 16 participants enrolled, started 2018-10-16. Conditions recorded: Glioblastoma and Glioblastoma, Adult. Interventions recorded: DNX-2440 injection.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03714334
- Phase: 1
- Setting: Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma
- Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT03714334: https://clinicaltrials.gov/study/NCT03714334

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [DNX-2440](https://onco.cc/drugs/dnx-2440/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct03714334.json